About nuvation bio inc - NUVB
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
NUVB At a Glance
Nuvation Bio, Inc.
1500 Broadway
New York, New York 10036
| Phone | 1-332-208-6102 | Revenue | 7.87M | |
| Industry | Biotechnology | Net Income | -567,939,000.00 | |
| Sector | Health Technology | Employees | 220 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
NUVB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 90.808 |
| Price to Book Ratio | 1.938 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.325 |
| Enterprise Value to Sales | 28.091 |
| Total Debt to Enterprise Value | 0.04 |
NUVB Efficiency
| Revenue/Employee | 35,786.364 |
| Income Per Employee | -2,581,540.909 |
| Receivables Turnover | 0.483 |
| Total Asset Turnover | 0.014 |
NUVB Liquidity
| Current Ratio | 9.035 |
| Quick Ratio | 9.035 |
| Cash Ratio | 8.631 |
NUVB Profitability
| Gross Margin | 1.423 |
| Operating Margin | -2,128.248 |
| Pretax Margin | -7,213.756 |
| Net Margin | -7,213.756 |
| Return on Assets | -97.743 |
| Return on Equity | -106.265 |
| Return on Total Capital | -120.147 |
| Return on Invested Capital | -105.967 |
NUVB Capital Structure
| Total Debt to Total Equity | 1.922 |
| Total Debt to Total Capital | 1.886 |
| Total Debt to Total Assets | 1.649 |
| Long-Term Debt to Equity | 0.209 |
| Long-Term Debt to Total Capital | 0.205 |